4-(3-Amino-5-bromo-1H-pyrazolo[3,4-b]pyridin-6-yl)-phenol | 583039-77-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-(3-Amino-5-bromo-1H-pyrazolo[3,4-b]pyridin-6-yl)-phenol
• 英文别名: 4-(3-Amino-5-bromo-1H-pyrazolo[3,4-b]pyridin-6-yl)phenol；4-(3-amino-5-bromo-2H-pyrazolo[3,4-b]pyridin-6-yl)phenol
• CAS: 583039-77-4
• 化学式: C₁₂H₉BrN₄O
• 分子量: 305.134
• InChiKey: UWFDKOQUFGPKST-UHFFFAOYSA-N

物化性质

• 沸点：
  558.7±45.0 °C(Predicted)
• 密度：
  1.789±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  87.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4-Ethyl-piperazin-1-yl)-butyryl chloride 、 4-(3-Amino-5-bromo-1H-pyrazolo[3,4-b]pyridin-6-yl)-phenol 在 吡啶 作用下， 生成 N-[5-Bromo-6-(4-hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-4-(4-ethyl-piperazin-1-yl)-butyramide
  参考文献：
  名称：

  6-Aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3)

  摘要：

  A novel series of 6-aryl-pyrazolo[3,4-b]pyridines has been identified that are potent inhibitors of glycogen synthase kinase-3 (GSK-3).(C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00645-0
• 作为产物：
  描述：

  3-吡啶甲腈,1,2-二氢-6-(4-甲氧苯基)-2-羰基- 在 N-溴代丁二酰亚胺(NBS) 、 三溴化硼 、 一水合肼 、 三氯氧磷 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 生成 4-(3-Amino-5-bromo-1H-pyrazolo[3,4-b]pyridin-6-yl)-phenol
  参考文献：
  名称：

  6-Aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3)

  摘要：

  A novel series of 6-aryl-pyrazolo[3,4-b]pyridines has been identified that are potent inhibitors of glycogen synthase kinase-3 (GSK-3).(C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00645-0

文献信息

• [EN] PYRAZOLOPYRIDINE DERIVATIVES<br/>[FR] DERIVES DE PYRAZOLOPYRIDINE
  申请人：GLAXO GROUP LTD

  公开号：WO2003068773A1

  公开（公告）日：2003-08-21

  Certain compounds of formula (I), or a salt thereof, or a solvate thereof, wherein R1, R2, R3 and R4 are as defined in the specification, a procees for the preparation of such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds in medicine. For the treatment of conditions associated with a need for inhibition of GSK-3 such as diabetes, conditions associated with diabetes, chronic neurodegenerative conditions including dementias such as Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy, subacute sclerosing panencephalitic parkinsonism, postencephalitic parkinsonism, pugilistic encephalitis, guam parkinsonism-dementia complex, Picks's disease, corticobasal degeneration, frontotemporal dementia, Huntingdon's disease, AIDS associated dementia, amyotrophic lateral sclerosis, multiple sclerosis and neurotraumatic diseases such as acute stroke, mood disorders such as schizophrenia and bipolar disorders, promotion of functional recovery post stroke, cerebral bleeding (for example, due to solidary cerebral amyloid angiopathy), hair loss, obesity, atherosclerotic cardiovascular disease, hypertension, polycystic ovary syndrome, syndrome X, ischaemia, traumatic brain injury, cancer, leukopenia, Down's syndrome, Lewy body disease, inflammation, and immunodeficiency.